Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Christopher Degnan
Christopher Degnan is recorded as CFO and Chief Accounting Officer at UroGen Pharma Ltd. (URGN). Earlier roles on record: CFO at Galera Therapeutics, Inc. (GRTXD) until August 31, 2024. UroGen Pharma Ltd. reported in an 8-K filed October 9, 2024 that Christopher Degnan was appointed principal accounting officer, effective October 8, 2024. UroGen Pharma Ltd. reported in an 8-K filed October 9, 2024 that Christopher Degnan was appointed Chief Financial Officer, effective October 8, 2024. Galera Therapeutics, Inc. reported in an 8-K filed August 14, 2024 that Christopher Degnan was terminated as Chief Financial Officer, effective August 31, 2024. The proxy statement of Galera Therapeutics, Inc. reports total compensation of $834,865 for Christopher Degnan in fiscal 2022, including a base salary of $432,250. Disclosed compensation is on record for 5 fiscal years. Christopher Degnan has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for UroGen Pharma Ltd. on September 15, 2026.
“the Company appointed Christopher Degnan as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.”
UroGen Pharma Ltd. Form 8-K, filed October 9, 2024
· Read the filing
“On October 7, 2024, the Company appointed Christopher Degnan as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.”
UroGen Pharma Ltd. Form 8-K, filed October 9, 2024
· Read the filing
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
